Automated Insulin Delivery Gets Expanded: New Approval for Pregnancy, Growing Evidence in Type 2

Managing Type 1 diabetes during pregnancy requires careful insulin adjustment, as hormone changes shift insulin needs significantly. An automated insulin delivery system has now received approval specifically for use during pregnancy—marking an important expansion of tools available to pregnant people with T1D.

This approval reflects growing recognition that pregnancy and the postpartum period present unique challenges that standard diabetes management tools may not fully address.

The first six months after giving birth bring major lifestyle changes—less sleep, new routines, and the demands of caring for a newborn. A recent clinical trial tested whether automated insulin delivery could help people maintain good blood sugar control during this demanding time.

The study followed 57 pregnant women with Type 1 diabetes for six months after delivery. Those using an automated insulin delivery system (the CamAPS FX system) achieved better time in their target blood sugar range compared to those using standard insulin therapy with continuous glucose monitoring alone. These results suggest that automated systems can help manage the practical challenges of the postpartum period, when attention to diabetes care can easily get derailed.

The findings are noteworthy because clinical guidelines in the UK and other countries didn't previously address how to use these newer systems specifically during the postpartum period.

Closed-loop or automated insulin delivery systems—sometimes called the 'artificial pancreas'—have moved from experimental to standard diabetes care for many people with Type 1 diabetes. These systems use a continuous glucose monitor, an insulin pump, and an algorithm to automatically adjust insulin delivery throughout the day and night.

Researchers continue to test these systems in real-world settings and in specialized situations like pregnancy. Their widespread adoption reflects consistent evidence that they improve blood sugar control and reduce the burden of constant manual adjustments.

While automated insulin delivery remains the main tool for Type 1 diabetes, researchers are exploring its use in Type 2 diabetes as well—particularly in people who require insulin. A large real-world analysis of over 26,000 people using the MiniMed 780G system in Type 2 diabetes showed consistent improvements in blood sugar control across different patient groups.

At the same time, other therapies are also advancing. Islet transplantation—a procedure in which insulin-producing cells from a donor are implanted—remains an option for people with complicated Type 1 diabetes. Experts expect that closed-loop systems and transplant therapies will likely continue to coexist rather than one replacing the other entirely, since they serve different needs and patient populations.

Origin: Breakthrough T1D (News report). Evidence: News report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.